论文部分内容阅读
文章简介近年来肾癌发病率上升幅度在恶性肿瘤中排名第一。临床治疗表明,肾癌对放疗和化疗均不敏感,以索拉非尼和舒尼替尼为代表的靶向抗肿瘤药物是晚期肾癌的一线治疗药物,但对转移性肾癌的疗效十分有限,并且容易产生耐药。因此,发现并确证治疗肾癌特异性药物作用新靶标是一项十分紧迫并意义重大的任务。SPOP是泛素连接酶E3家族成员Cul3结合底物蛋白
Article introduction Rising rates of renal cell carcinoma in recent years ranked first in malignant tumors. Clinical treatment showed that renal cell carcinoma is not sensitive to radiotherapy and chemotherapy, and targeted anti-tumor drugs represented by sorafenib and sunitinib are the first-line therapies for advanced renal cell carcinoma, but their effects on metastatic renal cell carcinoma are very high Limited, and prone to resistance. Therefore, finding and confirming a new target for the treatment of renal cancer-specific drugs is a very urgent and significant task. SPOP is a member of the ubiquitin ligase E3 family Cul3 binding substrate protein